Xenter’s Latest TAVR Product Could Wipe Out Competition

The Transcatheter aortic valve replacement (TAVR) industry is estimated to hit $6.8bn by the end of 2023.

Xenter’s new TAVR equipment has the potential to rival Boston Scientific and Medtronic with their latest wireless model.

As aortic stenosis becomes more widespread there is more demands for non-intrusive methods, Xenter’s guidewire could replace traditional procedures. A number of other companies may release their own versions of Xenter’s product to maintain their position in the billion-dollar industry.

If Xenter’s Guidewire becomes an implemented tool, the TAVR industry may see changes in the near future and large competitors should expect an impact on their sales.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.